Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Global Finance Journal ; 54, 2022.
Artículo en Inglés | Web of Science | ID: covidwho-2307721

RESUMEN

Does face-to-face interaction still facilitate information transfer despite proliferating communication technologies? We use the COVID-19 collapse in such interactions to examine their influence on information flow in the stock market around earnings announcements. Using daily, county-level abnormal mobility of U.S. residents to proxy for face-to-face interaction, we find that firms located in counties with lower abnormal mobility experience a weaker immediate price reaction to earnings announcements and a larger post-announcement drift. Our findings suggest that lower face-to-face interactions dampen price discovery in financial markets, and that investor attention is a potential mechanism of this effect.

2.
Australian Journal of Management ; 48(1):13575.0, 2023.
Artículo en Inglés | Scopus | ID: covidwho-2241474

RESUMEN

This article examines institutions' investment strategies towards environmental and social (E&S) stocks in the first quarter of 2020, coinciding with the COVID-19 pandemic outbreak. Backed with both institutional- and firm-level analyses, we find that institutional investors shift towards stocks with higher E&S performance. The high E&S portfolios exhibit lower risk and return characteristics, outperforming (underperforming) their peers on market-down (-up) days. Further analysis shows this shift towards E&S is not a permanent transition, rather it reversed with the market rebound in the second quarter, thereby suggesting that the underlying driver of institutional E&S investment strategy in the pandemic is downside-risk protection. JEL Classification: G01, G12, G23, M14 © The Author(s) 2022.

3.
16th International Conference of the Learning Sciences, ICLS 2022 ; : 282-288, 2022.
Artículo en Inglés | Scopus | ID: covidwho-2168899

RESUMEN

In recent years, a large body of evidence demonstrates that active learning through engaging college students in a discussion leads to increased learning outcomes. However, more empirical studies are needed to understand its effectiveness in online classes. In Experiment 1, students majoring in veterinary medicine were randomly assigned to three conditions: Lecture and Review, Lecture and Discussion, and Self-study and Discussion. Post-test results showed that the two discussion groups achieved significantly higher scores than the review group. Moreover, among the two discussion groups, the self-study group performed better than the lecture group. To reconsider the reliability and generalizability of our study we conducted Experiment 2 in which, we compared the performance of the two discussion conditions again for students majoring in social science. Our findings indicate that not only online discussions but active learning activities such as self-studying before the discussion is also crucial for students' learning. © ISLS.

4.
International Journal of Advanced and Applied Sciences ; 9(6):90-95, 2022.
Artículo en Inglés | Web of Science | ID: covidwho-1918248

RESUMEN

This paper uses the modified gravity model to measure the intensity of tourism economic connection in 11 prefecture-level cities in Shanxi Province from 2016 to 2020. From the perspective of the social network, the density and core-periphery area of the tourism economic network's spatial structure are explored. The research shows that: From 2016 to 2020, the overall tourism economic connection in Shanxi Province shows a growing trend, and the differentiation phenomenon between the central region and the southern and northern regions is more obvious. There is an unbalanced spatial structure of the tourism economy in all prefecture-level cities in Shanxi province. On the whole, the network density shows a growing trend. The various indexes of Taiyuan, the capital city of Shanxi Province, are obviously better than other cities' indexes. The number of core areas of the tourism economy changes little. These areas are closely connected but the strengthening trend is not obvious. The relations within the periphery region are not strong, and the connection between the periphery region and the core region is also weak. The connection of the regional tourism economy is strongly dependent on tourism resources endowment and transportation accessibility. The spatial structure of the tourism economy network is under the great influence of policy suggestions and planning. This study provides a certain theoretical basis for the formulation of tourism economic development strategy in Shanxi Province. The limitation is that the impact of COVID-19 on tourism development has not been specifically analyzed. (C) 2022 The Authors. Published by IASE.

5.
Eur Rev Med Pharmacol Sci ; 26(10): 3760-3770, 2022 05.
Artículo en Inglés | MEDLINE | ID: covidwho-1876425

RESUMEN

OBJECTIVE: This meta-analysis aims to assess the susceptibility to and clinical outcomes of COVID-19 in autoimmune inflammatory rheumatic disease (AIRD) and following AIRD drug use. MATERIALS AND METHODS: We included observational and case-controlled studies assessing susceptibility and clinical outcomes of COVID-19 in patients with AIRD as well as the clinical outcomes of COVID-19 with or without use of steroids and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). RESULTS: Meta-analysis including three studies showed that patients with AIRD are not more susceptible to COVID-19 compared to patients without AIRD or the general population (OR: 1.11, 95% CI: 0.58 to 2.14). Incidence of severe outcomes of COVID-19 (OR: 1.34, 95% CI: 0.76 to 2.35) and COVID-19 related death (OR: 1.21, 95% CI: 0.68 to 2.16) also did not show significant difference. The clinical outcomes of COVID-19 among AIRD patients with and without csDMARD or steroid showed that both use of steroid (OR: 1.69, 95% CI: 0.96 to 2.98) or csDMARD (OR: 1.35, 95% CI: 0.63 to 3.08) had no effect on clinical outcomes of COVID-19. CONCLUSIONS: AIRD does not increase susceptibility to COVID-19, not affecting the clinical outcome of COVID-19. Similarly, the use of steroids or csDMARDs for AIRD does not worsen the clinical outcome.


Asunto(s)
Antirreumáticos , Enfermedades Autoinmunes , Tratamiento Farmacológico de COVID-19 , Enfermedades Reumáticas , Antirreumáticos/uso terapéutico , Humanos , Incidencia , Enfermedades Reumáticas/tratamiento farmacológico , Enfermedades Reumáticas/epidemiología
6.
Zhonghua Yi Xue Za Zhi ; 102(7): 463-467, 2022 Feb 22.
Artículo en Chino | MEDLINE | ID: covidwho-1698668

RESUMEN

In early 2020, an outbreak of coronavirus disease 2019 (COVID-19) epidemic happened in China. In the following three months, 42 600 medical personnels and more than 9 000 public health employees were "rushed out" of their own position and onto Wuhan and other areas in Hubei Province. They helped to strengthen the treatment of severe cases and the isolation of mild cases, and actively carried out community screenings, and eventually won victory in the defense of Wuhan. During the normalization stage of prevention and control of the epidemic of COVID-19, China adopted the expanded preventive strategy by focusing on widely implement PCR testing, and integrate general and emergency departments to improve the performance of public health system. In this stage, China put out the cluster of epidemics that have occurred in several places one after another, and effectively controlled the spread of the epidemic in 2 to 3 incubation periods. In the stage of "dynamic zeroing", China emphasized the strategy of "grasping early, grasping the basics", focused on specific measures such as precise prevention in key areas. The rule of golden 24 hours was used to control the spread of the epidemic within one incubation period. During the epidemic, China continues to adopt active prevention and control strategies. This self-confidence and determination depends on adhering to the leadership of the Communist Party of China, the distinct essence of medical and health services, and significant advantages of social governance on health.


Asunto(s)
COVID-19 , Epidemias , China/epidemiología , Brotes de Enfermedades , Epidemias/prevención & control , Humanos , SARS-CoV-2
7.
European Review for Medical and Pharmacological Sciences ; 25(23):7390-7397, 2021.
Artículo en Inglés | Web of Science | ID: covidwho-1576450

RESUMEN

OBJECTIVE: Although remdesivir (GS-5734) has recently demonstrated clinical benefits against the pandemic outbreak of coronavirus disease 2019 (COVID-19), neuropsychological adverse reactions (ADRs) remain to be examined in real-world settings. Therefore, we aimed to identify and characterize the neuropsychological ADRs associated with remdesivir use. MATERIALS AND METHODS: We obtained data for this international pharmacovigilance cohort study from individual case safety reports (ICSRs) in a World Health Organization database (VigiBase) from the first report on remdesivir on February 17, 2020, until August 30, 2020 (n=1,403,532). ADRs reported to be relevant to remdesivir were compared with the full database by using a Bayesian neural network method to calculate the information component (IC). RESULTS: A total of 2,107 reported cases of neuropsychological ADRs suspected to be associated with remdesivir were identified from among all ICSRs in the database during the observation period. Although 108 neuropsychological ADRs (64 neurologic events and 44 psychologic events) were reported in association with the medication, no statistically significant pharmacovigilance signal could be detected;the ICO25 value was negative for all of the neuropsychological dysfunctions (anxiety [n=13, 0.62%], seizures [n=12, 0.57%], lethargy [n=6, 0.28%], agitation [n=5, 0.25%], cerebral infarction [n=3, 0.14%]. ischemic stroke [n=3, 0.14%], and hemiparesis [n=3, 0.14%]). CONCLUSIONS: Our study demonstrates that remdesivir, a novel drug applied to the treatment of COVID-19, does not have a significant association with adverse neurologic or psychiatric reactions in the real-world setting.

8.
Eur Rev Med Pharmacol Sci ; 25(20): 6397-6407, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: covidwho-1503071

RESUMEN

OBJECTIVE: Coronavirus disease 2019 (COVID-19) is a pandemic and leading cause of death. Beyond the deaths directly caused by the virus and the suicides related to the psychological response to the dramatic changes as socioeconomic related to the pandemic, there might also be suicides related to the inflammatory responses of the infection. Infection induces inflammation as a cytokine storm, and there is an increasing number of studies that report a relationship between infection and suicide. MATERIALS AND METHODS: We searched the World Health Organization status report and the PubMed database for keywords (COVID-19, suicide, infection, inflammation, cytokines), and reviewed five cytokine pathways between suicide and inflammation using two meta-analyses and two observational studies starting from November 31, 2020, focusing on the relationship between suicide and inflammation by infection. First, we discussed existing evidence explaining the relationship between suicidal behaviors and inflammation. Second, we summarized the inflammatory features found in COVID-19 patients. Finally, we highlight the potential for these factors to affect the risk of suicide in COVID-19 patients. RESULTS: Patients infected with COVID-19 have high amounts of IL-1ß, IFN-γ, IP10, and MCP1, which may lead to Th1 cell response activation. Also, Th2 cytokines (e.g., IL-4 and IL-10) were increased in COVID-19 infection. In COVID-19 patients, neurological conditions, like headache, dizziness, ataxia, seizures, and others have been observed. CONCLUSIONS: COVID-19 pandemic can serve as a significant environmental factor contributing directly to increased suicide risk; the role of inflammation by an infection should not be overlooked.


Asunto(s)
COVID-19/inmunología , Citocinas/inmunología , Suicidio , COVID-19/psicología , Humanos , Factores de Riesgo , Suicidio/psicología
9.
Eur Rev Med Pharmacol Sci ; 24(24): 13089-13097, 2020 12.
Artículo en Inglés | MEDLINE | ID: covidwho-1000855

RESUMEN

OBJECTIVE: Recently, two influential articles that reported the association of (hydroxy)chloroquine or angiotensin converting enzyme (ACE) inhibitors and coronavirus disease 2019 (COVID-19) mortality were retracted due to significant methodological issues. Therefore, we aimed to analyze the same clinical issues through an improved research method and to find out the differences from the retracted papers. We systematically reviewed pre-existing literature, and compared the results with those of the retracted papers to gain a novel insight. MATERIALS AND METHODS: We extracted common risk factors identified in two retracted papers, and conducted relevant publication search until June 26, 2020 in PubMed. Then, we analyzed the risk factors for COVID-19 mortality and compared them to those of the retracted papers. RESULTS: Our systematic review demonstrated that most demographic and clinical risk factors for COVID-19 mortality were similar to those of the retracted papers. However, while the retracted paper indicated that both (hydroxy)chloroquine monotherapy and combination therapy with macrolide were associated with higher risk of mortality, our study showed that only combination therapy of hydroxychloroquine and macrolide was associated with higher risk of mortality (odds ratio 2.33; 95% confidence interval 1.63-3.34). In addition, our study demonstrated that use of ACE inhibitors or angiotensin receptor blockers (ARBs) was associated with reduced risk of mortality (0.77; 0.65-0.91). CONCLUSIONS: When analyzing the same clinical issues with the two retracted papers through a systematic review of randomized controlled trials and relevant cohort studies, we found out that (hydroxy)chloroquine monotherapy was not associated with higher risk of mortality, and that the use of ACE inhibitors or ARBs was associated with reduced risk of mortality in COVID-19 patients.


Asunto(s)
Antagonistas de Receptores de Angiotensina/uso terapéutico , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , COVID-19/mortalidad , Inhibidores Enzimáticos/uso terapéutico , Hidroxicloroquina/uso terapéutico , Retractación de Publicación como Asunto , Factores de Edad , Pueblo Asiatico/estadística & datos numéricos , Población Negra/estadística & datos numéricos , COVID-19/epidemiología , COVID-19/inmunología , Enfermedad de la Arteria Coronaria/epidemiología , Bases de Datos Factuales , Diabetes Mellitus/epidemiología , Quimioterapia Combinada , Insuficiencia Cardíaca/epidemiología , Humanos , Hipertensión/epidemiología , Huésped Inmunocomprometido/inmunología , Difusión de la Información , Macrólidos/uso terapéutico , Obesidad/epidemiología , Puntuaciones en la Disfunción de Órganos , Factores Protectores , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Ensayos Clínicos Controlados Aleatorios como Asunto , Factores de Riesgo , SARS-CoV-2 , Índice de Severidad de la Enfermedad , Factores Sexuales , Fumar/epidemiología , Tratamiento Farmacológico de COVID-19
10.
Eur Rev Med Pharmacol Sci ; 24(22): 11926-11933, 2020 11.
Artículo en Inglés | MEDLINE | ID: covidwho-962026

RESUMEN

OBJECTIVE: Hematologic cancer patients with Coronavirus Disease 2019 (COVID-19) tend to have a more serious disease course than observed in the general population. Herein, we comprehensively reviewed existing literature and analyzed clinical characteristics and mortality of patients with hematologic malignancies and COVID-19. MATERIALS AND METHODS: Through searching PubMed until June 03, 2020, we identified 16 relevant case studies (33 cases) from a total of 45 studies that have reported on patients with COVID-19 and hematologic malignancies. We investigated the clinical and laboratory characteristics including type of hematologic malignancies, initial symptoms, laboratory findings, and clinical outcomes. Then, we compared those characteristics and outcomes of patients with hematologic malignancies and COVID-19 to the general population infected with COVID-19. RESULTS: The median age was 66-year-old. Chronic lymphocytic leukemia was the most common type of hematologic malignancy (39.4%). Fever was the most common symptom (75.9%). Most patients had normal leukocyte counts (55.6%), lymphocytosis (45.4%), and normal platelet counts (68.8%). In comparison to patients with COVID-19 without underlying hematologic malignancies, dyspnea was more prevalent (45.0 vs. 24.9%, p=0.025). Leukocytosis (38.9 vs. 9.8%, p=0.001), lymphocytosis (45.4 vs. 8.2%, p=0.001), and thrombocytopenia (31.3 vs. 11.4%, p=0.036) were significantly more prevalent and lymphopenia (18.2 vs. 57.4%, p=0.012) less prevalent in patients with hematologic malignancies. There were no clinical and laboratory characteristics predicting mortality in patients with hematologic malignancies. Mortality was much higher in patients with hematologic malignancies compared to those without this condition (40.0 vs. 3.6%, p<0.001). CONCLUSIONS: Co-occurrence of hematologic malignancies and COVID-19 is rare. However, due to the high mortality rate from COVID-19 in this vulnerable population, further investigation on tailored treatment and management is required.


Asunto(s)
COVID-19/complicaciones , Disnea/fisiopatología , Neoplasias Hematológicas/complicaciones , Linfocitosis/sangre , Linfopenia/sangre , Trombocitopenia/sangre , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , COVID-19/sangre , COVID-19/mortalidad , COVID-19/fisiopatología , Niño , Preescolar , Disnea/epidemiología , Femenino , Fiebre/epidemiología , Fiebre/fisiopatología , Humanos , Leucemia Linfocítica Crónica de Células B/complicaciones , Leucocitosis/sangre , Leucocitosis/epidemiología , Linfocitosis/epidemiología , Linfoma no Hodgkin/complicaciones , Linfopenia/epidemiología , Masculino , Persona de Mediana Edad , Mieloma Múltiple/complicaciones , Trombocitopenia/epidemiología , Adulto Joven
11.
Clin Microbiol Infect ; 26(9): 1171-1177, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: covidwho-622944

RESUMEN

BACKGROUND: Corticosteroids are commonly used as adjuvant therapy for acute respiratory distress syndrome by many clinicians because of their perceived anti-inflammatory effects. However, for patients with severe viral pneumonia, the corticosteroid treatment is highly controversial. OBJECTIVES: The purpose of this review is to systematically evaluate the effect and potential mechanism of corticosteroid administration in pandemic viral pneumonia. SOURCES: We comprehensively searched all manuscripts on corticosteroid therapy for influenza, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and SARS coronavirus 2 (SARS-CoV-2) viral pneumonia from the PubMed, EMBASE, Web of Science and Cochrane Library databases. CONTENT: We systematically summarized the effects of corticosteroid therapy for pandemic viral pneumonia and the potential mechanism of action for corticosteroids in coronavirus disease 2019 (COVID-19). IMPLICATIONS: Observational studies showed that corticosteroid treatment was associated with increased mortality and nosocomial infections for influenza and delayed virus clearance for SARS-CoV and MERS-CoV. Limited data on corticosteroid therapy for COVID-19 were reported. Corticosteroids were used in about a fifth of patients (670/2995, 22.4%). Although clinical observational studies reported the improvement in symptoms and oxygenation for individuals with severe COVID-19 who received corticosteroid therapy, case fatality rate in the corticosteroid group was significantly higher than that in the non-corticosteroid group (69/443, 15.6% versus 56/1310, 4.3%). Compared individuals with non-severe disease, those with severe disease were more likely to receive corticosteroid therapy (201/382, 52.6% versus 201/1310, 15.3%). Although there is no evidence that corticosteroid therapy reduces mortality in people with COVID-19, some improvements in clinical symptoms and oxygenation were reported in some clinical observational studies. Excessive inflammatory response and lymphopenia might be critical factors associated with severity of and mortality from COVID-19. Sufficiently powered randomized controlled trials with rigorous inclusion/exclusion criteria and standardized dose and duration of corticosteroids are needed to verify the effectiveness and safety of corticosteroid therapy.


Asunto(s)
Corticoesteroides/efectos adversos , Corticoesteroides/uso terapéutico , Tratamiento Farmacológico de COVID-19 , Neumonía Viral/tratamiento farmacológico , COVID-19/mortalidad , Infecciones por Coronavirus/tratamiento farmacológico , Infección Hospitalaria , Humanos , Gripe Humana/tratamiento farmacológico , Gripe Humana/mortalidad , Estudios Observacionales como Asunto , Neumonía Viral/mortalidad , Síndrome Respiratorio Agudo Grave/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA